TITLE

N-cadherin impedes proliferation of the multiple myeloma cancer stem cells

AUTHOR(S)
Sadler, Nicole M.; Harris, Britney R.; Metzger, Brittany A.; Kirshner, Julia
PUB. DATE
October 2013
SOURCE
American Journal of Blood Research;2013, Vol. 3 Issue 4, following p271
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Multiple myeloma (MM) is an incurable malignancy of the plasma cells localized to the bone marrow. A rare population of MM cancer stem cells (MM-CSCs) has been shown to be responsible for maintaining the pull of residual disease and to contribute to myeloma relapse. The stem cells are found in a bone marrow niche in contact with the stromal cells that are responsible for maintaining the proliferative quiescence of the MM-CSC and regulate its self-renewal and differentiation decisions. Here we show that both MM and bone marrow stromal cells express N-cadherin, a cell-cell adhesion molecule shown to maintain a pool of leukemic stem cells. Inhibition of N-cadherin using a neutralizing antibody led to an increase in the MM cell proliferation. A decrease in MM cell adhesion to the bone marrow stroma was observed in the first 24 hours of co-culture followed by a 2.3-30-fold expansion of the adherent cells. Moreover, inhibition of N-cadherin led to a 4.8-9.6-fold expansion of the MM-CSC population. Surprisingly, addition of the N-cadherin antagonist peptide resulted in massive death of the non-adherent MM cells, while the viability of the adherent cells and MM-CSCs remained unaffected. Interestingly, the proliferative effects of N-cadherin inhibition were not mediated by the nuclear translocation of β-catenin. Taken together, our findings demonstrate the crucial role of N-cadherin in regulating MM cell proliferation and viability and open an interesting avenue of investigation to understand how structural modifications of N-cadherin can affect MM cell behavior. Our findings suggest that targeting N-cadherin may be a useful therapeutic strategy to treat MM in conjunction with an agent that has anti-MM-CSC activity.
ACCESSION #
94750440

 

Related Articles

  • PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Noll, Jacqueline E.; Vandyke, Kate; Hewett, Duncan R.; Mrozik, Krzysztof M.; Bala, Rachel J.; Williams, Sharon A.; Kok, Chung H.; Zannettino, Andrew C. W. // Journal of Hematology & Oncology;10/7/2015, Vol. 8 Issue 1, p1 

    Background: Multiple myeloma (MM) is an incurable haematological malignancy characterised by the clonal proliferation of malignant plasma cells within the bone marrow. We have previously identified pituitary tumour transforming gene 1 (Pttg1) as a gene that is significantly upregulated in the...

  • Multiple Myeloma.  // Current Medical Literature: Leukemia & Lymphoma;2010, Vol. 18 Issue 3, p94 

    The article discusses two studies on multiple myeloma, "Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma" and "CR Represents an Early Index of Potential Long Survival in Multiple Myeloma." The first study noted that...

  • Biological and clinical implications of cancer stem cells in primary brain tumors. Maugeri-Saccà, Marcello; DiMartino, Simona; DeMaria, Ruggero // Frontiers in Oncology;Jan2013, Vol. 3, p1 

    Despite therapeutic advances, glioblastoma multiforme (GBM) remains a lethal disease. The infiltrative nature of this disease and the presence of a cellular population resistant to current medical treatments account for the poor prognosis of these patients. Growing evidence indicates the...

  • Assessment of Bone Marrow Fibrosis and Angiogenesis in Monitoring Patients With Multiple Myeloma. Babarović, Emina; Valković, Toni; Štifter, Sanja; Budisavljević, Ivana; Seili-Bekafigo, Irena; Duletić-Načinović, Antica; Lučin, Ksenija; Jonjić, Nives // American Journal of Clinical Pathology;Jun2012, Vol. 137 Issue 6, p871 

    The aim of our study was to emphasize the importance of accurate and standardized techniques for detailed monitoring of the microenvironment in multiple myeloma (MM). Bone marrow fibrosis, angiogenesis, and plasma cell infiltrates in bone marrow biopsy (BMB) samples at the time of diagnosis and...

  • Bilateral pleural effusion as an initial manifestation of multiple myeloma: A case report and literature review. AI-GUI JIANG; YU-TIAN YANG; XIAO-YAN GAO; HUI-YU LU // Experimental & Therapeutic Medicine;2015, Vol. 9 Issue 3, p1040 

    Multiple myeloma (MM) is a rare type of malignant hematological neoplasm. Although primarily involving the bone marrow, MM has a significant risk of metastasizing to other organs and may present with various clinical symptoms. However, the involvement of the respiratory system in the course of...

  • The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma. Sager, Sait; Ergül, Nurhan; Ciftci, Hediye; Cetin, Güven; Güner, Sebnem İzmir; Cermik, Teyfik Fikret; Ergül, Nurhan; Cetin, Güven; Güner, Sebnem Izmir // Skeletal Radiology;Jul2011, Vol. 40 Issue 7, p843 

    Objective: The aim of this study was to describe the role of positron emission tomography/computed tomography (PET/CT) with fluorine-18 fluorodeoxyglucose (FDG) in the detection of skeletal and visceral involvement in patients with MM (multiple myeloma) at the initial diagnosis and...

  • Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2. Manni, S; Toscani, D; Mandato, E; Brancalion, A; Quotti Tubi, L; Macaccaro, P; Cabrelle, A; Adami, F; Zambello, R; Gurrieri, C; Semenzato, G; Giuliani, N; Piazza, F // Leukemia (08876924);Oct2014, Vol. 28 Issue 10, p2094 

    The article presents a study which aims to address the CK2 inhibition consequences on the multiple myeloma (MM) cells and growth signals survival delivered in the bone marrow (BM) microenvironment. The data show that CK2 inhibition is less toxic for osteoblast cell lines as equated with...

  • Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Kastritis, E; Terpos, E; Moulopoulos, L; Spyropoulou-Vlachou, M; Kanellias, N; Eleftherakis-Papaiakovou, E; Gkotzamanidou, M; Migkou, M; Gavriatopoulou, M; Roussou, M; Tasidou, A; Dimopoulos, M A // Leukemia (08876924);Apr2013, Vol. 27 Issue 4, p947 

    Asymptomatic multiple myeloma (AMM) is characterized by a constant risk of progression to symptomatic myeloma. To evaluate previously recognized risk factors and to identify high-risk features we analyzed 96 patients with AMM and at least 18 months of follow-up. The progression rate at 1,2, and...

  • Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Larsen, J T; Kumar, S K; Dispenzieri, A; Kyle, R A; Katzmann, J A; Rajkumar, S V // Leukemia (08876924);Apr2013, Vol. 27 Issue 4, p941 

    A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of progression. We retrospectively studied the predictive value of the serum (FLC) assay in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics